Enoxaparin augments alpha-1-antitrypsin inhibition of TMPRSS2, a promising drug combination against COVID-19.

Although a double-blind, placebo-controlled study showed that remdesivir therapy reduced the recovery time from COVID-19 by ~ 4 days and showed a trend toward improved mortality 29 , an extensive analysis showed that remdesivir did not affect on the use of mechanical ventilation, length of hospital stay, or mortality 30 .

also in 53,322 other papers